Navigation Links
Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program

SEATTLE, Nov. 2, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has been awarded $977,917 in grants under the Therapeutic Discovery Tax Credit program that was enacted under the U.S. government's Patient Protection and Affordable Care Act. The program targets projects that show potential to produce new therapies, address unmet medical needs, reduce the long-term growth of health care costs and advance the goal of curing cancer. CTI was awarded the grants for CTI's programs pixantrone, OPAXIO, brostallicin and bisplatinates which are all focused in the area of oncology.  

"We are pleased that the U.S. Department of Health and Human Services recognizes the potential impact that CTI's research and drugs could have for patients and specifically in advancing the effort to make cancer more treatable," said James A. Bianco, M.D., CEO of Cell Therapeutics. "This program is also recognition of the importance of the contribution the biotechnology industry is making to U.S. healthcare. These grants will allow CTI to further advance its product candidates in an effort to treat areas that have significant unmet medical needs."

About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

Sign up for email alerts and get RSS feeds at our Web site,

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties associated with preclinical and clinical developments in the biopharmaceutical industry in general, and CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling its product candidates, that CTI cannot guarantee that its product candidates will produce new therapies, address unmet medical needs, reduce the long-term growth of health care costs or advance the goal of curing cancer, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.Media Contact:Dan Eramian T: 206.272.4343C: 206.854.1200E: Contact:Ed BellT: 206.282.7100Lindsey Jesch LoganT: 206.272.4347F: 206.272.4434E: Information Contact:T: 800.715.0944E:

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
2. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
3. Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021
4. Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference
5. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
6. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
7. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
8. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
9. Cell Therapeutics Third Quarter Net Loss Decreases by 68% in 2010 Compared to 2009
10. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... 2015  Array BioPharma Inc. (Nasdaq: ARRY ... Ron Squarer , will present at the ... The public is welcome to participate in the ... website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron Squarer, ... p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... , Nueva York , ... Biomedical Devices (ABD), fabricante del Avery Breathing Pacemaker ... Anders Jonzon , MD; Ph.D. como consultor clínico. ...   --> Foto - ... --> El doctor Jonzon es un fisiólogo ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - ... surgeon specializing in both surgical and non-surgical treatments, announced the expansion of his ... Facial Plastic Surgery. , Highly trained and nationally recognized for his natural ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination of ... a way for homeless people to have a more dignified and comfortable night’s ... whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... 2015 , ... Young patients with a wide variety of dental needs can ... S. Lele, who are pediatric dentists in Tucson, AZ . Unlike traditional treatment ... system causes minimal discomfort and bleeding to the patient during treatment and the following ...
Breaking Medicine News(10 mins):